Effects of Pleuran (Β–Glucan from Pleurotus Ostreatus) Supplementation on Incidence and Duration of COPD Exacerbations

Минов, Јордан; Bislimovska-Karadzhinska, Jovanka; Petrova, Tatjana; Vasilevska, Kristin; Stoleski, Sasho; Mijakoski, Dragan

doi:10.3889/oamjms.2017.198

Cited by 6 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we found significantly lower incidence of exacerbations, as well as their significantly shorter duration in the study subjects receiving pleuran as compared to their incidence and duration in those who did not receive pleuran. Similar findings were obtained in our study on the effects of pleuran on the incidence and duration of exacerbations in patients with COPD who received the same doses of pleuran over the 3-month period [15]. Similar findings were reported by several studies that investigated effects of pleuran on incidence, duration, and severity of respiratory infections in children [38], [39].…”

Section: Discussionsupporting

confidence: 91%

“…Study subjects from the examined groups had similar demographic characteristics, as well as characteristics related to their disease (mean duration of the disease after diagnosis, severity, etiology, lung function, microbiological findings in the stable phase of the disease, accompanying COPD, etc.). We found a high prevalence of active and passive smokers in both examined groups, which was similar to their prevalence registered in our previous studies [15], [32], [33].…”

Section: Discussionsupporting

confidence: 91%

“…The aim of the present study was to assess the effects of pleuran on the incidence and duration of exacerbations in patients with BE. This study is a continuation of our investigation into the effects of pleuran on the incidence and severity of bacterial exacerbations in chronic obstructive airway diseases, following on from a previous study in which the incidence and severity of exacerbations were investigated in patients with stable chronic obstructive pulmonary disease (COPD) treated with pleuran (COPD patients with accompanying BE were not included in the study) [15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of Pleuran (β-glucan from Pleurotus ostreatus) Supplementation on Incidence and Duration of Bronchiectasis Exacerbations

Минов

Stoleski

Karadžinska-Bislimovska

et al. 2020

Open Access Maced J Med Sci

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Patients with non-cystic fibrosis bronchiectasis (BE) have frequent exacerbations that are causes of significant morbidity and sometimes mortality, and which it is desirable to prevent. AIM: We aimed to assess the effects of pleuran on the incidence and duration of exacerbations in patients with BE. METHODS: A prospective, observational, open-label, and active-controlled study was realized as a comparison of the frequency and duration of exacerbations between a group of patients with BE (30 patients, 14 males and 16 females, aged 44–72 years) who received a combination supplement containing pleuran 100 mg, Vitamin C 60 mg and zinc 5 mg over a 3-month period and a group of patients with BE (31 patients, 15 males and 16 females, aged 45–74 years) treated over a 3-month period with a combination supplement containing Vitamin C 60 mg and zinc 5 mg. RESULTS: Over the study period, altogether 46 exacerbations were documented (19 in the patients receiving pleuran and 27 in the patients who did not receive pleuran), nine of which required hospital treatment (four in the patients receiving pleuran [21.5%] and five in the patients who did not receive pleuran [18.6%]). The mean number of exacerbations over the study period was significantly lower in the patients receiving pleuran (0.6 ± 0.4) as compared to the mean number in the patients who did not receive pleuran (0.8 ± 0.3) (p = 0.0297). The mean duration of exacerbations, expressed in days, needed for cure or clinical improvement in the patients receiving pleuran (11.2 ± 1.7 days) was significantly shorter than that of exacerbations in the patients who did not receive pleuran (12.4 ± 1.3 days) (p = 0.0029). We found significantly lower incidence and significantly shorter duration of exacerbations in the patients with BE who received pleuran as compared to their incidence and duration in the patients with BE who did not receive pleuran. CONCLUSION: Our findings indicated a need for further investigations in this domain to define the possible role of pleuran in the prevention of BE exacerbations.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Pleuran (β-glucan from Pleurotus ostreatus) Supplementation on Incidence and Duration of Bronchiectasis Exacerbations

Минов

Stoleski

Karadžinska-Bislimovska

et al. 2020

Open Access Maced J Med Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…For instance, cytokines (IL-1 β , IL-6, and TNF- α ), NO synthase, and NF- κ B of the RAW264.7 cells were upregulated upon treatment with Dictyophora indusial polysaccharides [ 14 ]. The β -glucan from Pleurotus Ostreatus , which is another species of mushroom, decreased the incidence and duration of bacterial exacerbations in patients with COPD [ 27 ]. Moreover, Astragalus membranaceus extract reduced the inflammatory response induced by lipopolysaccharide from E .…”

Section: Discussionmentioning

confidence: 99%

Medicinal Foods, YT and RH Combination, Suppress Cigarette Smoke-Induced Inflammation and Oxidative Stress by Inhibiting NF-κB/ERK Signaling Pathways

Wang

Luo

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Cigarette smoke is a risk factor for Chronic Obstructive Pulmonary Disease (COPD). Given the lack of COPD curative treatment, dietary management for COPD patients has become important. This study investigated whether the medicinal foods (YT and RH) could suppress cigarette smoke exposure-induced inflammation and oxidative stress. Methods. Chronic pulmonary inflammation in male C57 mice was induced by a 4-week exposure to cigarette smoke (CS). The medicinal foods YT and RH were orally administered 1 week prior to CS exposure. The protective effects were assessed by measuring the pulmonary function and histopathological evaluations. Inflammatory cell numbers and cytokines levels in BALF and blood serum were analyzed by enzyme-linked immunosorbent assay (ELISA). Malondialdehyde (MDA) and superoxide dismutase (SOD) levels of the lung were analyzed. Furthermore, the levels of phosphorylated ERK and NF-κB in both the mice lungs and RAW264.7 cells were also detected. Results. YT and RH combination (YT + RH) significantly improved pulmonary function and suppressed the inflammation, including cell number and cytokines in BALF relative to the CS group; histological examination revealed protective effects of YT + RH in the lungs of mice exposed to CS. Moreover, the MDA level in the lung of the YT + RH group of mice was lower, the SOD activity was higher, and in vitro treatment of YT and RH combination attenuated reactive oxygen species (ROS) expression in mouse macrophage RAW264.7 cells stimulated with cigarette smoke (CSE). YT + RH combination significantly reduced the expression of pNF-κB and pERK in the lung tissues and macrophage stimulated with CSE. Conclusions. YT and RH combination attenuates cigarette smoke-induced inflammation and oxidative stress through inhibition of the NF-κB/ERK signaling pathway.

show abstract

“…Studies from various clinical trials and expert opinion reports have shown that the immunosuppressants (IS) are effective in management of COPD in comparison to other conventional treatment [15,16]. IS such as cyclosporine, tacrolimus, CpG (TLR-9 agonists) and few monoclonal antibodies have shown effective results in treating AECB by targeting the prime inflammatory pathways [17,18].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness, safety and cost analysis of add-on pidotimod in maintenance therapy for exacerbation of chronic obstructive pulmonary disease in adults

Goyal¹

2020

IJIRM

View full text Add to dashboard Cite

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is the sudden worsening in airway function and respiratory symptoms in patients with COPD which range from self-limited diseases to episodes of florid respiratory failure requiring mechanical ventilation. An average patient with COPD might experience 2 episodes of AECOPD per year and 10% of these episodes require hospitalization. Pidotimod, an immunostimulant, has shown promising results in conditions with underlying cause of suppressed cell-mediated immunity like chronic bronchitis and recurrent respiratory tract infection (RRTI). The current study evaluated the safety, efficacy and cost effectiveness of Pidotimod in adult Indian patients with COPD as an add-on drug in maintenance therapy of acute exacerbations. In this prospective, open label, single arm, single centre study, Pidotimod was administered as an add-on therapy for 2 months in 114 patients (≥ 18 years and ≤ 55years; mean age: 59.51± 8.66 years) with COPD having experienced two or more exacerbation that required antibiotics. The study comprised of screening visit, enrolment and 3 follow-up visits (at the end of 2, 6 and 12 months). Of the 111 patients at baseline, only one patient had an AECB episode at 2 and 6 months. At the end of 12 months, none of the patient had an AECB. Only one subject was prescribed with antibiotic treatment at the end of 2 and 6 months. No episodes of either exacerbations or antibiotic prescription at the end of 12 months were reported. A significant reduction (p<0.05) in mean modified British Medical Research Council (mMRC) score was observed at the end of 6 and 12 months from baseline. There were no hospitalizations at any of the follow-up visits. Only one patient (0.9%) was taking reliever/rescue medication. The mean expenses significantly reduced at the end of 2 and 6 months of treatment with Pidotimod. Pidotimod was well tolerated. In conclusion, Pidotimod is safe, effective and cost effective as maintenance therapy for exacerbation of COPD, when added to the standard of care.

show abstract

Effects of Pleuran (Β–Glucan from Pleurotus Ostreatus) Supplementation on Incidence and Duration of COPD Exacerbations

Cited by 6 publications

References 19 publications

Effects of Pleuran (β-glucan from Pleurotus ostreatus) Supplementation on Incidence and Duration of Bronchiectasis Exacerbations

Effects of Pleuran (β-glucan from Pleurotus ostreatus) Supplementation on Incidence and Duration of Bronchiectasis Exacerbations

Medicinal Foods, YT and RH Combination, Suppress Cigarette Smoke-Induced Inflammation and Oxidative Stress by Inhibiting NF-κB/ERK Signaling Pathways

Effectiveness, safety and cost analysis of add-on pidotimod in maintenance therapy for exacerbation of chronic obstructive pulmonary disease in adults

Contact Info

Product

Resources

About